1. Clinical impact of very early recurrence after conversion surgery for stage IV gastric cancer
- Author
-
Atsushi Morito, Kojiro Eto, Masaaki Iwatsuki, Tasuku Toihata, Keisuke Kosumi, Shiro Iwagami, Yoshifumi Baba, Yuji Miyamoto, Naoya Yoshida, and Hideo Baba
- Subjects
conversion surgery ,prognostic nutritional index ,stage IV gastric cancer ,very early recurrence ,Surgery ,RD1-811 ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Abstract Background The development and improved response to chemotherapy has resulted in a survival benefit of conversion surgery (CS) for advanced gastric cancer (GC). However, this benefit is limited in some cases, such as in those with very early recurrence (VER). This study investigated the relationship between outcome and clinicopathological characteristics after CS for stage IV GC, and the risk factors for VER after CS. Methods We retrospectively studied 184 patients with stage IV GC who initially underwent chemotherapy, including 36 patients who underwent CS between May 2007 and January 2022. We evaluated the long‐term outcome after CS for stage IV GC and the clinicopathological characteristics of the patients who underwent CS. Results Median survival times (MSTs) in the chemotherapy alone and CS groups were 13.4 and 36.5 months, respectively (p
- Published
- 2024
- Full Text
- View/download PDF